Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting-Reference-Cited by-同舟云学术

Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting

Published:2021-08 Issue:4 Volume:51 Page:685-691
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Choi Seulggie,Ghang Byeongzu,Jeong Seogsong,Choi Daein,Lee Jeong Seok,Park Sang Min,Lee Eun Young

Funder

Bristol-Myers Squibb

Ministry of Health and Welfare

Korea Health Industry Development Institute

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference34 articles.

1. Rheumatoid arthritis;Smolen;Lancet,2016

2. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2016

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update;Smolen;Ann Rheum Dis,2020

4. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis;Bathon;N Engl J Med,2000

5. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial;Weinblatt;Arthritis Rheum,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis;The Korean Journal of Internal Medicine;2024-09-01

2. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

3. Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023;Reumatología Clínica;2024-05

4. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023;Reumatología Clínica (English Edition);2024-05

5. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review;Journal of Managed Care & Specialty Pharmacy;2023-09